ERCC1 Activators

Common ERCC1 Activators include, but are not limited to Cisplatin CAS 15663-27-1, Carboplatin CAS 41575-94-4, Oxaliplatin CAS 61825-94-3, Etoposide (VP-16) CAS 33419-42-0 and Fluorouracil CAS 51-21-8.

The Excision Repair Cross-Complementation Group 1 (ERCC1) protein is a pivotal player in the nucleotide excision repair (NER) pathway, a crucial mechanism that addresses a spectrum of DNA lesions induced by ultraviolet (UV) radiation, environmental mutagens, and certain metabolic byproducts. These DNA lesions can lead to mutations, compromising genomic integrity and driving cellular dysfunctions. ERCC1, in conjunction with its binding partner XPF, forms a structure-specific endonuclease that introduces incisions on the DNA strand adjacent to the lesion. This action facilitates the removal of the damaged segment, followed by accurate DNA synthesis to restore the original sequence. Given its central role in the NER pathway, ERCC1 is instrumental in maintaining genomic stability and preventing the accumulation of mutations.

Activators of ERCC1 are molecules or compounds that amplify the expression, stability, or activity of ERCC1. These activators may function by promoting the transcription or translation of the ERCC1 gene, enhancing the stability of the ERCC1 protein, or fostering its endonuclease activity in partnership with XPF. The presence and action of ERCC1 activators can significantly influence the efficiency and fidelity of the NER pathway, bolstering the cellular capacity to counteract DNA damage and uphold genomic stability. Delving deeper into the realm of ERCC1 activators provides rich insights into the intricate regulation of DNA repair processes. As our understanding of genome maintenance continues to expand, the role of ERCC1 and its activators stands as a testament to the cell's relentless efforts to preserve its genetic blueprint against a myriad of challenges.